ERT hires Linda Deal

To head its Health Outcomes Research initiatives

ERT, a US headquartered provider of clinical services and customisable medical devices, has appointed Linda Deal to lead its Health Outcomes Research initiatives.

Most recently Deal was the Immunology Patient Reported Outcomes (PRO) lead at Janssen Pharma, a division of Johnson & Johnson. Prior to this, she headed the PRO Centre in Global Health Outcomes Assessment (GHOA) at Wyeth Research, now part of Pfizer. She has also supported health economics and outcomes research for Wyeth, Research Triangle Institute, and Glaxo Welcome.

In the context of health outcomes research ERT’s ePRO solutions are said to offer the advantages of simplicity, mobility and immediacy of use over traditional paper-based methods.

The ePRO suite comprises an IVR solution (VIAPhone), a digital pen (VIAPen), a handheld device (VIAPad) and an Internet application (VIAWeb).

You may also like

Regulatory

ERT introduces solution to measure Lung Clearance Index

Solution provides greater data granularity to measure disease progression in respiratory trials where standard spirometry is insufficient
Regulatory

ERT recognised for improving and accelerating clinical research

Company named finalist for PACT Technology Company of the Year Award
Regulatory

Exco InTouch launches Gather and redefines the use of mobile technology in clinical trials

New product suite supports patients, sites and sponsors throughout the clinical journey
Regulatory

Scottish Equity Partners takes minority stake in Exco InTouch

Will provide a initial investment of £3m to accelerate mobile patient communication solutions
Regulatory

Almac and Exco InTouch form alliance

To deliver patient compliance as well as ePRO services using multiple technologies
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory

NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case

The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Subscribe now